flymetothemoon2
Nov 19, 2:39 AM
$ABCL
Part 2)
Now consider the parallel recruitment efforts across medical affairs, pharmacovigilance, commercial manufacturing, regulatory affairs and drug delivery devices.
These are expensive, specialized leadership positions.
AbCellera could outsource many of these functions. Instead, it appears to be investing in permanent internal capabilities that can be leveraged across multiple therapeutic programs.
Coming just one day after Carl Hansen discussed advancing ABCL635 independently through Phase 3 and potentially commercializing it without a partner, the recruitment strategy deserves particular attention.
I believe investors are still underappreciating the magnitude of this transformation.
AbCellera isn’t just building the infrastructure to bring one drug to market. It’s building the infrastructure to repeatedly bring drugs to market.
0 replies